Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW...
-
Alkeus Pharmaceuticals, Inc., today announced that results from its study of gildeuretinol in geographic atrophy were presented at AAO 2024.
-
Results from Study of Oral Gildeuretinol for Geographic Atrophy Secondary to Age-Related Macular Degeneration to be Presented as Late-Breaker During Retina Subspecialty Day Positive Data from TEASE...
-
INBS successfully completes in-clinic testing proposed to the FDA earlier this year in its clinical study plan.
-
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
-
Science 37 opens new, state-of-the-art facility, to enhance collaboration and improve patient recruitment and study support for clinical trials.
-
Intelligent Bio Solutions Inc. (INBS) partners with CenExel to perform a method comparison clinical study as part of the Company’s FDA clinical study plan.
-
NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
-
Patent notice extends global coverage for breakthrough discovery, with potential for treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases, including Scleroderma, Nonalcoholic...
-
NEWARK, Del, Feb. 07, 2023 (GLOBE NEWSWIRE) -- The global Clinical Trials Market is anticipated to augment at a flourishing CAGR of 4.41% over the forecast period from 2023 to 2033. The global...